Douglas Love, Annexon CEO (Annexon)
July 2, 2020 06:58 AM EDT
Financing

IPO bound? A Bay Area biotech grabs a mega-round on the road to a piv­otal neu­rode­gen­er­a­tion pro­gram

John Carroll

Editor & Founder

South San Fran­cis­co-based An­nex­on has added $100 mil­lion to its cash re­serves, along with a new ros­ter of mar­quee in­vestors back­ing their play on the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

Apol­lo makes a deal worth up to $926M; Abeona re­sub­mits gene ther­a­py

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times